$3.65
0.164.58%
At close: -
$3.67
0.020.55%
After Hours: Apr 11, 7:42 PM EDT
Comments
Loading...
Amylyx Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:AMLX | Benzinga
Amylyx Pharmaceuticals Inc has a consensus price target of $27.33 based on the ratings of 11 analysts. The high is $54 issued by Citigroup on March 14, 2023. The low is $4 issued by Goldman Sachs on July 12, 2024. The 3 most-recent analyst ratings were released by Mizuho, HC Wainwright & Co., and HC Wainwright & Co. on April 7, 2025, March 5, 2025, and December 5, 2024, respectively. With an average price target of $10.33 between Mizuho, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 181.56% upside for Amylyx Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Mizuho
HC Wainwright & Co.
Baird
Goldman Sachs
Deutsche Bank
1calculated from analyst ratings
Analyst Ratings for Amylyx Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/07/2025 | Buy Now | 90.74% | Mizuho | Graig Suvannavejh53% | $3 → $7 | Upgrade | Neutral → Outperform | Get Alert |
| 03/05/2025 | Buy Now | 226.98% | HC Wainwright & Co. | Andrew Fein52% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 12/05/2024 | Buy Now | 226.98% | HC Wainwright & Co. | Andrew Fein52% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 11/18/2024 | Buy Now | 199.73% | Baird | Joel Beatty64% | $3 → $11 | Upgrade | Neutral → Outperform | Get Alert |
| 11/08/2024 | Buy Now | 226.98% | HC Wainwright & Co. | Andrew Fein52% | $8 → $12 | Maintains | Buy | Get Alert |
| 10/18/2024 | Buy Now | 117.98% | HC Wainwright & Co. | Andrew Fein52% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 07/12/2024 | Buy Now | 8.99% | Goldman Sachs | Chris Shibutani55% | $3 → $4 | Maintains | Neutral | Get Alert |
| 07/10/2024 | Buy Now | 117.98% | HC Wainwright & Co. | Andrew Fein52% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 06/24/2024 | Buy Now | 117.98% | HC Wainwright & Co. | Andrew Fein52% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 05/14/2024 | Buy Now | -18.26% | Mizuho | Graig Suvannavejh53% | $4 → $3 | Maintains | Neutral | Get Alert |
| 05/10/2024 | Buy Now | 117.98% | HC Wainwright & Co. | Andrew Fein52% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 04/11/2024 | Buy Now | 117.98% | HC Wainwright & Co. | Andrew Fein52% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 04/11/2024 | Buy Now | -18.26% | Baird | Joel Beatty64% | $4 → $3 | Maintains | Neutral | Get Alert |
| 04/08/2024 | Buy Now | 117.98% | HC Wainwright & Co. | Andrew Fein52% | $8 → $8 | Maintains | Buy | Get Alert |
| 03/12/2024 | Buy Now | 117.98% | HC Wainwright & Co. | Andrew Fein52% | $42 → $8 | Maintains | Buy | Get Alert |
| 03/11/2024 | Buy Now | 117.98% | Deutsche Bank | Neena Bitritto-Garg60% | $36 → $8 | Maintains | Buy | Get Alert |
| 03/11/2024 | Buy Now | 8.99% | Goldman Sachs | Chris Shibutani55% | $40 → $4 | Downgrade | Buy → Neutral | Get Alert |
| 03/11/2024 | Buy Now | — | Leerink Partners | Marc Goodman73% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 03/11/2024 | Buy Now | 8.99% | Baird | Joel Beatty64% | $37 → $4 | Downgrade | Outperform → Neutral | Get Alert |
| 03/08/2024 | Buy Now | — | Evercore ISI Group | Umer Raffat43% | — | Downgrade | Outperform → In-Line | Get Alert |
| 03/08/2024 | Buy Now | 771.93% | Mizuho | Graig Suvannavejh53% | $27 → $32 | Reiterates | Buy → Buy | Get Alert |
| 01/03/2024 | Buy Now | 908.17% | Baird | Joel Beatty64% | → $37 | Initiates | → Outperform | Get Alert |
| 12/21/2023 | Buy Now | 635.69% | Mizuho | Graig Suvannavejh53% | $46 → $27 | Maintains | Buy | Get Alert |
| 12/12/2023 | Buy Now | 880.93% | Deutsche Bank | Neena Bitritto-Garg60% | → $36 | Initiates | → Buy | Get Alert |
| 11/10/2023 | Buy Now | 989.92% | Goldman Sachs | Chris Shibutani55% | $46 → $40 | Maintains | Buy | Get Alert |
| 11/10/2023 | Buy Now | 1044.41% | HC Wainwright & Co. | Andrew Fein52% | $50 → $42 | Maintains | Buy | Get Alert |
| 08/11/2023 | Buy Now | 1262.4% | HC Wainwright & Co. | Andrew Fein52% | → $50 | Reiterates | Buy → Buy | Get Alert |
| 07/27/2023 | Buy Now | 1262.4% | HC Wainwright & Co. | Andrew Fein52% | → $50 | Reiterates | Buy → Buy | Get Alert |
| 07/24/2023 | Buy Now | 1235.15% | Goldman Sachs | Chris Shibutani55% | $45 → $49 | Upgrade | Neutral → Buy | Get Alert |
| 05/31/2023 | Buy Now | 1262.4% | HC Wainwright & Co. | Andrew Fein52% | → $50 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | Buy Now | 1262.4% | Mizuho | Graig Suvannavejh53% | $52 → $50 | Maintains | Buy | Get Alert |
| 05/12/2023 | Buy Now | 1262.4% | HC Wainwright & Co. | Andrew Fein52% | → $50 | Reiterates | Buy → Buy | Get Alert |
| 03/31/2023 | Buy Now | 1316.89% | Mizuho | Graig Suvannavejh53% | → $52 | Initiates | → Buy | Get Alert |
| 03/14/2023 | Buy Now | 1180.65% | Goldman Sachs | Chris Shibutani55% | $41 → $47 | Maintains | Neutral | Get Alert |
| 03/14/2023 | Buy Now | 1371.39% | Citigroup | Itay Michaeli47% | $51 → $54 | Maintains | Buy | Get Alert |
| 03/14/2023 | Buy Now | 1262.4% | HC Wainwright & Co. | Andrew Fein52% | → $50 | Reiterates | → Buy | Get Alert |
| 02/15/2023 | Buy Now | 1262.4% | HC Wainwright & Co. | Andrew Fein52% | → $50 | Reiterates | → Buy | Get Alert |
| 01/05/2023 | Buy Now | 1262.4% | B of A Securities | Geoff Meacham59% | → $50 | Initiates | → Buy | Get Alert |
| 10/24/2022 | Buy Now | 1262.4% | HC Wainwright & Co. | Andrew Fein52% | $35 → $50 | Maintains | Buy | Get Alert |
| 10/03/2022 | Buy Now | 1262.4% | Citigroup | Neena Bitritto-Garg60% | $48 → $50 | Maintains | Buy | Get Alert |
| 09/09/2022 | Buy Now | 989.92% | Goldman Sachs | Chris Shibutani55% | $22 → $40 | Maintains | Neutral | Get Alert |
| 09/08/2022 | Buy Now | 1207.9% | Citigroup | Neena Bitritto-Garg60% | $35 → $48 | Maintains | Buy | Get Alert |
| 09/08/2022 | Buy Now | 1262.4% | SVB Leerink | Marc Goodman73% | $31 → $50 | Maintains | Outperform | Get Alert |
| 07/06/2022 | Buy Now | 908.17% | Citigroup | Neena Bitritto-Garg60% | $33 → $37 | Maintains | Buy | Get Alert |
| 06/14/2022 | Buy Now | 799.18% | Citigroup | Neena Bitritto-Garg60% | $32 → $33 | Maintains | Buy | Get Alert |
| 05/25/2022 | Buy Now | 472.21% | Citigroup | Neena Bitritto-Garg60% | → $21 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Amylyx Pharmaceuticals (AMLX) stock?
The latest price target for Amylyx Pharmaceuticals (NASDAQ:AMLX) was reported by Mizuho on April 7, 2025. The analyst firm set a price target for $7.00 expecting AMLX to rise to within 12 months (a possible 90.74% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Amylyx Pharmaceuticals (AMLX)?
The latest analyst rating for Amylyx Pharmaceuticals (NASDAQ:AMLX) was provided by Mizuho, and Amylyx Pharmaceuticals upgraded their outperform rating.
When was the last upgrade for Amylyx Pharmaceuticals (AMLX)?
The last upgrade for Amylyx Pharmaceuticals Inc happened on April 7, 2025 when Mizuho raised their price target to $7. Mizuho previously had a neutral for Amylyx Pharmaceuticals Inc.
When was the last downgrade for Amylyx Pharmaceuticals (AMLX)?
The last downgrade for Amylyx Pharmaceuticals Inc happened on March 11, 2024 when Goldman Sachs changed their price target from $40 to $4 for Amylyx Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Amylyx Pharmaceuticals (AMLX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amylyx Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amylyx Pharmaceuticals was filed on April 7, 2025 so you should expect the next rating to be made available sometime around April 7, 2026.
Is the Analyst Rating Amylyx Pharmaceuticals (AMLX) correct?
While ratings are subjective and will change, the latest Amylyx Pharmaceuticals (AMLX) rating was a upgraded with a price target of $3.00 to $7.00. The current price Amylyx Pharmaceuticals (AMLX) is trading at is $3.67, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.